Antiviral Res

1. SCHREIBER A, Rodner F, Oberberg N, Anhlan D, et al
   The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance.
   Antiviral Res. 2024 Mar 2:105840. doi: 10.1016/j.antiviral.2024.105840.
   

   >> Share

   
   

   
   BMC Cancer

2. LIANG Y, Zhong D, Zhang Z, Su Y, et al
   Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma.
   BMC Cancer. 2024;24:291.
   

   >> Share

   
   

   
   HIV Med

3. FURSA O, Bannister W, Neesgaard B, Podlekareva D, et al
   SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohort.
   HIV Med. 2024 Mar 3. doi: 10.1111/hiv.13620.
   

   >> Share

   
   

   
   J Med Virol

4. XIE M, Wang Z, Zhao F, Li Y, et al
   Structure-based design of diarylpyrimidines and triarylpyrimidines as potent HIV-1 NNRTIs with improved metabolic stability and drug resistance profiles.
   J Med Virol. 2024;96:e29502.
   

   >> Share

   
   

   
   PLoS One

5. SACKEYA E, Beru MM, Angmortey RN, Opoku DA, et al
   Survival trends among people living with human immunodeficiency virus on antiretroviral treatment in two rural districts in Ghana.
   PLoS One. 2024;19:e0290810.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share